🔔 Meeting of Interest in Cancer Drug Development: 2026 AAADV Workshop
Registration is NOW OPEN for the 2026 AAADV Workshop! 📅 Date: November 5–6, 2026 📍 Location: North Bethesda Marriott Hotel & Conference Center (In-Person & Virtual Participation Available) 📝 View the draft program: https://aaadv.org/2026-aaadv-workshop-agenda/...
ACT EU Multi-Stakeholder Platform: Meeting Documents from 18 June 2026
The meeting documents from ACT-EU MSP meeting held on 18 June 2026 are available now on the ACT EU website. These include presentations from the European Commission on Progress with the BioTech Act and specifically its clinical trial related aspects - present by C....
Report on the ACT EU Webinar Regarding Contractual Agreements
The report on the ACT EU webinar regarding contractual agreements, held on 16 April, has been published on the ACT EU website. The webinar explored how clinical site agreements affect the start-up of clinical trials and shared national and European experiences on...
Final: ICH E6(R3) GCP Annex 2
📢 ICH E6(R3) GCP Annex 2 was finalized and published by ICH on 3 June 2026. It covers pragmatic and decentralized elements, as well as the use of real-world data (RWD)—topics frequently discussed in CDDF meetings. The guidance also offers valuable insights into...
Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Transparency and Risk Assessment” (16 June 2026)
The CDDF is pleased to share the key takeaways from our live webinar series – “AI and Big Data AI in Drug Development: Transparency and Risk Assessment” held on 16 June 2026. This webinar included a lecture by Dr. Weida Tong (FDA) followed by a 30-minute Q&A...
![[MESSAGE FROM ACT EU – Request for stakeholders’ input on the guideline to simplify the clinical trials application package for use during Public Health Emergencies (PHEs).]](https://cddf.org/wp-content/uploads/2026/06/Copy-of-PUBLICATION-Annual-Repport-2024-Is-available-6-400x250.jpg)
[MESSAGE FROM ACT EU – Request for stakeholders’ input on the guideline to simplify the clinical trials application package for use during Public Health Emergencies (PHEs).]
ACT EU has developed the guideline to simplify the clinical trials application package for use during PHEs. The package consists of: 1️⃣ A guidance document on the simplified application package for clinical trials targeting a PHE 2️⃣ Annex I: Part I language...
CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova
🔔📢 CDDF’s New Board Announcement: Welcoming Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova The Cancer Drug Development Forum (CDDF) is pleased to announce the appointment of Dr. Agnes Saint-Raymond and Ms. Jana Pelouchova to its Board of Directors. We look forward to...
Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Use of AI in Clinical Trials” (12 May 2026)
The CDDF is pleased to share the key takeaways from our live webinar series – “AI and Big Data AI in Drug Development: Use of AI in clinical trials” held on 12 May 2026. This webinar included a lecture by Dr. James Gulley (NIH) followed by a 30-minute Q&A...
![[ACT EU Workplan for 2026-2027 – Version 4, May 2026]](https://cddf.org/wp-content/uploads/2026/05/Capture-400x250.jpg)
[ACT EU Workplan for 2026-2027 – Version 4, May 2026]
The ACT EU workplan for 2026 – 2027 has been adopted by the ACT EU Steering Group and is now published. The workplan reflects the revised ACT EU objectives and takes into account recent legislative and policy developments including the proposed Biotech Act, the...